1. Home
  2. CRAI vs SVRA Comparison

CRAI vs SVRA Comparison

Compare CRAI & SVRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo CRA International Inc.

CRAI

CRA International Inc.

HOLD

Current Price

$165.22

Market Cap

1.2B

ML Signal

HOLD

Logo Savara Inc.

SVRA

Savara Inc.

HOLD

Current Price

$5.07

Market Cap

1.1B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
CRAI
SVRA
Founded
1965
2007
Country
United States
United States
Employees
N/A
N/A
Industry
Other Consumer Services
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.2B
1.1B
IPO Year
1998
2009

Fundamental Metrics

Financial Performance
Metric
CRAI
SVRA
Price
$165.22
$5.07
Analyst Decision
Buy
Buy
Analyst Count
1
9
Target Price
★ $245.00
$7.33
AVG Volume (30 Days)
89.6K
★ 1.4M
Earning Date
05-07-2026
05-13-2026
Dividend Yield
★ 1.48%
N/A
EPS Growth
★ 20.77
N/A
EPS
★ 8.14
N/A
Revenue
★ $751,583,000.00
N/A
Revenue This Year
$7.82
N/A
Revenue Next Year
$5.14
$430.87
P/E Ratio
$19.91
★ N/A
Revenue Growth
★ 9.33
N/A
52 Week Low
$132.17
$3.34
52 Week High
$227.29
$7.01

Technical Indicators

Market Signals
Indicator
CRAI
SVRA
Relative Strength Index (RSI) 44.75 44.35
Support Level $152.37 $4.77
Resistance Level $166.99 $5.48
Average True Range (ATR) 5.22 0.22
MACD -0.30 -0.02
Stochastic Oscillator 46.90 40.14

Price Performance

Historical Comparison
CRAI
SVRA

About CRAI CRA International Inc.

CRA International Inc is a consulting firm specializing in providing economic, financial and management consulting services. The company provides advisory services on economic and financial matters related to litigation and regulatory proceedings, and advises corporations on business and performance-related matters. Its consulting services are organized into two areas: litigation, regulatory and financial consulting, and management consulting. The company's clients include domestic and foreign companies, government agencies, public and private utilities, and national and international trade associations. It derives revenues by providing professional and consulting services. Geographically, the maximum revenue is derived from the United States, followed by United Kingdom and other regions.

About SVRA Savara Inc.

Savara Inc is a clinical-stage biopharmaceutical company. It is focused on rare respiratory diseases. It has one segment specialty pharmaceuticals within the respiratory system. The company's main product candidate, molgramostim, is an inhaled granulocyte-macrophage colony-stimulating factor (GM-CSF) in Phase 3 development for autoimmune pulmonary alveolar proteinosis (aPAP).

Share on Social Networks: